Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Liabilities and Shareholders Equity: 2012-2025

Historic Liabilities and Shareholders Equity for Ptc Therapeutics (PTCT) over the last 13 years, with Sep 2025 value amounting to $2.6 billion.

  • Ptc Therapeutics' Liabilities and Shareholders Equity rose 43.50% to $2.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.6 billion, marking a year-over-year increase of 29.48%. This contributed to the annual value of $1.7 billion for FY2024, which is 10.06% down from last year.
  • Ptc Therapeutics' Liabilities and Shareholders Equity amounted to $2.6 billion in Q3 2025, which was up 0.36% from $2.6 billion recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' Liabilities and Shareholders Equity registered a high of $2.7 billion during Q1 2025, and its lowest value of $1.3 billion during Q3 2023.
  • Its 3-year average for Liabilities and Shareholders Equity is $1.9 billion, with a median of $1.8 billion in 2024.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first dropped by 25.83% in 2023, then skyrocketed by 48.38% in 2025.
  • Ptc Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $1.9 billion in 2021, then decreased by 11.99% to $1.7 billion in 2022, then increased by 11.14% to $1.9 billion in 2023, then declined by 10.06% to $1.7 billion in 2024, then spiked by 43.50% to $2.6 billion in 2025.
  • Its Liabilities and Shareholders Equity was $2.6 billion in Q3 2025, compared to $2.6 billion in Q2 2025 and $2.7 billion in Q1 2025.